“Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s179. doi:10.25251/skin.7.supp.179.